evinova.com

What It Is

Evinova is a life sciences clinical development software and consulting service operated by Evinova AG. It is positioned around using AI and digital tools to accelerate clinical trial design, start-up, execution, and decision-making. Its background is as an independent healthtech business within the AstraZeneca group, serving pharmaceutical companies, CROs, research sites, and clinical trial sponsors.

Core Features and Architecture

The platform is divided into an AI clinical development platform, Unified Trial Solution, and consulting services. The AI platform focuses on protocol authoring, planning, predictive modeling, portfolio optimization, cost estimation, document automation, and real-time portfolio views. UTS covers decentralized clinical trials, remote patient monitoring, eCOA/ePRO, connected devices, telemedicine, home drug delivery, sample tracking, alerts, and real-time dashboards. For collaboration, patients, research sites, and sponsors can work within a unified experience, with support for single sign-on, role-based permissions, and site-managed workflows.

Pricing and Implementation

The official website does not publish packages, unit pricing, seat-based pricing, or usage-based billing, nor does it state whether a free plan or trial is available. Sales are mainly initiated through Contact Us and tailored consultations. Given its coverage of global clinical trials, GxP compliance, and implementation services, procurement is closer to an enterprise-level custom project, making it more suitable for organizations with larger budgets and higher compliance requirements.

Security, Compliance, and Integrations

Evinova discloses a fairly comprehensive enterprise security design, including TLS 1.3 encryption in transit, AES-256 encryption at rest, tenant isolation for customer data, customer-managed keys, SAML 2.0/OAuth 2.0, role-based access control, data localization, audit trails, and references to ICH E6, GxP, and regional regulations. For integrations, it supports open APIs, standardized data models, partner connections such as Veeva, and connectivity with CTMS, EDC, eTMF, analytics tools, and BYOM.

Pros, Cons, and Best Fit

Its strengths are its depth in clinical R&D scenarios, coverage across the full chain of patients, sites, and sponsors, and the availability of consulting and implementation teams. Multilingual support, operations in 50+ countries, and China-dedicated infrastructure are also helpful for multinational trials. The downsides are that pricing, trials, SLA details, and specific payment methods are not transparent, and the system’s complexity may not suit small single-site research teams.

China Access and Alternatives

Available information indicates that it has China-dedicated infrastructure, but it does not clarify domestic website access, cross-border data transfer, contract terms, or payment details. For that reason, China access is rated as “partially restricted.” Multinational pharmaceutical companies can compare it with Veeva, Medidata, Oracle Health Sciences, Florence, and Castor; China-based projects may also evaluate local clinical research digitization vendors such as Taimei Medical Technology.